Crescendo Biologics
Crescendo Biologics is building a pipeline of novel medicines based on our highly innovative VH antibody fragment platform. Crescendo’s unique transgenic mouse platform rapidly and predictably generates high-affinity human heavy chain-only antibodies using the natural process of in vivo B-cell development following immunisation. VH single domain fragments from these heavy chain-only antibodies require no humanisation, making this a rapid and reliable route to candidate quality VH therapeutics.